MARKET

EDIT

EDIT

Editas Medicine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

39.25
-1.11
-2.75%
Opening 12:21 03/05 EST
OPEN
42.41
PREV CLOSE
40.36
HIGH
42.94
LOW
36.10
VOLUME
2.18M
TURNOVER
--
52 WEEK HIGH
99.95
52 WEEK LOW
14.01
MARKET CAP
2.64B
P/E (TTM)
-19.6702
1D
5D
1M
3M
1Y
5Y
The Chairman of Editas Medicine, Inc. (NASDAQ:EDIT), James Mullen, Just Bought 250% More Shares
Simply Wall St. · 12h ago
Editas Medicine CEO buys company shares on the dip
Editas Medicine (EDIT) has surged ~2.5% in the post-market after its CEO James Mullen disclosed the purchase of 25K of company shares at $46.27 apiece to increase his stake to 35K shares.Editas
Seekingalpha · 19h ago
DJ Editas Medicine Price Target Cut to $40.00/Share From $45.00 by Morgan Stanley
Dow Jones · 3d ago
DJ Editas Medicine Is Maintained at Underweight by Morgan Stanley
Dow Jones · 3d ago
Morgan Stanley Maintains Underweight on Editas Medicine, Lowers Price Target to $40
Morgan Stanley analyst Matthew Harrison maintains Editas Medicine (NASDAQ:EDIT) with a Underweight and lowers the price target from $45 to $40.
Benzinga · 3d ago
--Analyst Actions: Morgan Stanley Adjusts Price Target on Editas Medicine to $40 From $45, Maintains Underweight Rating
MT Newswires · 3d ago
CRISPR and Cas Genes Market to Cross US$ 4.23 Bn by 2027
Mar 02, 2021 (Market Insight Reports) -- The global xxx market is anticipated to grow with a significant CAGR of 16.02% during the forecast period 2020 to...
Market Insight Reports · 3d ago
Editas Medicine Inc Files For Potential Mixed Shelf Offering; Size Not Disclosed
-Reuters
Reuters · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EDIT. Analyze the recent business situations of Editas Medicine through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EDIT stock price target is 52.83 with a high estimate of 81.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 447
Institutional Holdings: 59.01M
% Owned: 87.60%
Shares Outstanding: 67.36M
TypeInstitutionsShares
Increased
82
2.19M
New
128
1.16M
Decreased
69
5.55M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.30%
Pharmaceuticals & Medical Research
-1.18%
Key Executives
President/Chief Executive Officer/Director
James Mullen
Chief Financial Officer
Michelle Robertson
Executive Vice President
Lisa Michaels
Senior Vice President
Harry Gill
Other
Gad Berdugo
Director
Meeta Chatterjee
Independent Director
Andrew Hirsch
Independent Director
Jessica Hopfield
Independent Director
David Scadden
Independent Director
Akshay Vaishnaw
No Data
About EDIT
Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

Webull offers kinds of Editas Medicine Inc stock information, including NASDAQ:EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.